Sanifit Therapeutics S.a.

Universitat De Les Illes Balears

Laboratorios Sanifit, S.l.

Other

Numat Biomedical, S. L.

Laboratories Sanifit, S. L.

Laboratoris Sanifit, S.l.

Numat Medtech, S.l.

Bernat Isern Amengual

Joan Perello Bestard

Fernando Tur Espinosa

Maximo Encabo Alarcon

Eva Tur Tur

Eva Martin Becerra

Maria De Mar Benito Amengual

Pilar Sanchis Cortes

Ciriaco Maraschiello De Zuani

Irene Lentheric

Paula Mendoza De Las Heras

Antonia Costa Bauza

Rafael M Prieto Almirall

Carolina Salcedo Roca

Felix Grases Freixedas

Joan Perelló Bestard

Miguel David Ferrer Reynes

Pieter H Joubert

Félix Grases Freixedas

Marta Monjo Cabrer

Joana María Ramis Morey

María Del Mar Arriero Sánchez

Eva Martín Becerra

Rubén Henríquez Paláez

Antonia Costa-Bauza

Rafael Mara Prieto Almirall

Ramon Garcia Gonzalez

Marco Antonio Moreno Santurino

Joana Maria Ramis Morey

Maria Del Arriero Sanchez

Ruben Henriquez Palaez

Joan PerellÓ Bestard

Miquel David Ferrer REYNÉS

Iréne Lenthéric

Máximo Encabo Alarcón

Feliciano Grases Freixedas

Isabel Gomila MUÑOZ

Rubén HENRÍQUEZ PELÁEZ

María Del Mar Arriero SÁNCHEZ

Rafael Mará Prieto Almirall

Ramón GARCÍA GONZÁLEZ

Iréne LENTHÉRIC

María De Mar Benito Amengual

Máximo Encabo ALARCÓN

María Del Mar Benito Amengual

Pilar Sanchís Cortés

Antonia Costa-bauzá

Joan Perelló Berstard

Miquel David Ferrer Reynes

The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups R, wherein each R group means independently —OH, —OP(O)(OH)2 or —P(O)(OH)2, with the proviso that at least two R are independently selected from —P(O)(OH)2 and —OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200

The present invention provides processes for preparing soluble salts of inositol phosphate characterized by a low level of impurities. Processes for preparing soluble salts (e.g., alkali-metal or ammonium) of inositol phosphates (e.g., hexasodium or dodecasodium salts), and of inositol hexaphosphate in particular (e.g., NaIPand NaIP), are described. Also provided are pharmaceutical compositions, methods of use, combination treatments, kits, and articles of manufacture comprising soluble salts of inositol phosphates prepared according to the method of the invention.

Processes for the preparation of soluble salts of inositol phosphates

The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups R, wherein each R group means independently &#x2014;OH, &#x2014;OP(O)(OH)2 or &#x2014;P(O)(OH)2, with the proviso that at least two R are independently selected from &#x2014;P(O)(OH)2 and &#x2014;OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

Use of a derivative containing C&#x2014;O&#x2014;P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.

Use of derivatives containing C-O-P bonds in patients with kidney failure

The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups &#x2014;R, wherein each R group means independently &#x2014;OH, &#x2014;OP(O)(OH)2 or &#x2014;P(O)(OH)2, with the proviso that at least two R are independently selected from &#x2014;P(O)(OH)2 and &#x2014;OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

The present invention relates to a biocompatible implant comprising one or more metal(s), metal alloy(s), metal oxide(s) or a combination thereof, wherein a compound selected from the group consisting of an IP, an ester of an IP, and/or a pharmaceutically acceptable salt thereof, or a combination thereof, is/are covalently bound to at least a part of a metal, metal alloy or metal oxide surface of said biocompatible implant. The covalent bond between the IP and the metal, metal alloy or metal oxide surface can be further assisted by the use of a linker. An implant according to the invention provides for a modulated and/or improved osseointegrative effect when implanted into a body, such as a mammalian body, by virtue of the coating comprising covalently bound phytate.

Biocompatible implant

Use of a derivative containing C&#x2014;O&#x2014;P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimirnetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.

Use of derivatives containing C&#x2014;O&#x2014;P bonds in patients with kidney failure

The invention relates to a fixed-dose association of phytate and zinc in synergic proportions for use in the treatment of crystallization of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallization of hydroxyapatite in humans.

Fixed-dose association of phytate and zinc

The invention relates to a fixed-dose association of 5 phytate and zinc in synergic proportions for use in the treatment of crystallization of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said 10 association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallization of hydroxyapatite in humans.

The present invention relates to the use of myo-inositol hexaphosphate or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or treatment of a disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. These compounds may be utilized in the manufacture of functional foods, dietetic supplements, vitamin supplements, nutritional supplements, food supplements, or phytotherapeutic products having properties of inhibition of dissolution of crystals of calcium salts.

Use of phytate as agent inhibiting dissolution of crystals of calcium salts for the prevention of osteoporosis

Growing community of inventors

Palma De Mallorca, Spain

Bernat Isern Amengual